REGISTER LOG IN LIFE SCIENCES About NanoString Careers News Events Contact Us Go to Home Applications Products Elements™ TagSets Cancer Research nDesign™ Support Community Home | Webinar_list Request Info RSS Print Simultaneous Profiling of Pathogen and Host Responses During Infection with the NanoString nCounter Platform by Wenjie Xu, Technical Services Scientist Learn how nCounter® technology can advance your infectious disease research faster and more accurately with unprecedented sensitivity, reproducibility and ease of use. nCounter has been successfully used for identification and profiling of viruses, bacteria and fungi from real life infection samples. One single RNA isolation can generate paired data for both pathogen and host. Thanks to the automated and streamlined workflow, it takes less than 48 hours from sample collection to publication grade figures. Air Times June 10th 6:00 AM PST 9:00 AM PST 2:00 PM BST (London) 3:00 PM CEST (Germany, France) June 14th 7:30 AM IST (India) 10:00 AM CST (Beijing) Webinar Live during: Jul 27, 2016 at 6:00am Register now! Direct Link for Sharing Sporadic Early-onset Colon Cancer Expresses Unique Molecular Features by Jana Jandova , Ph.D Join us and learn about recent studies that have shown for the first time that NanoString nCounter PanCancer panel is suitable to access the expression profiling of FFPE samples. As early-onset CRC tumors mostly available in FFPE format, this approach will enable to analyze larget cohorts of especially early-onset CRC patients and help find novel molecular signatures characteristic to early-onset CRC and better understand the etiology of this unfortunate disease. Webinar Live during: Jul 20, 2016 at 9:00am Direct Link for Sharing Immune Gene Signature Predicts Clinical Outcome in Resected Stage II-III Melanoma by Yvonne Saenger MD, Biomarker development for melanoma has been limited by the challenge of isolating high-quality RNA for transcriptome-wide profiling from formalin-fixed and paraffin-embedded (FFPE) primary tumor specimens. Using NanoString technology, RNA from 40 stage II-III FFPE primary melanomas was analyzed and a 53-immune-gene panel predictive of non-progression (area under the curve (AUC)=0.920) was defined. The signature predicted disease-specific survival (DSS P Webinar Live during: Jul 13, 2016 at 9:00am On-Demand Direct Link for Sharing Gene Expression Signature Development: The Discovery Phase; State of the Field and Lessons Learned by Patrick Danaher, Ph.D., , Senior Biostatistician The long-touted field of gene expression diagnostics is finally hitting its stride, seeing a flurry of development activity and a trend of increasing acceptance from regulators, payers and doctors. This webinar, the second in our three-part series on Biomarker Discovery and Signature Development, will provide an in-depth view of GX signature development. We will start by discussing current trends in the field of gene expression diagnostics followed by a comprehensive view of the approaches that have led to successful signature development. Finally, we will explore the powerful strategies and pitfalls in the training of gene expression signature development. DATES/TIMES: Broadcast 1: 8 July, 2016 6:00 AM PST (USA) 2:00 PM BST / 3:00 PM CEST (UK/Europe) - - - - - - - - - - Broadcast 2: 8 July, 2016 9:00 AM PST (USA) 5:00 PM BST / 6:00 PM CEST (UK/Europe) - - - - - - - - - - Broadcast 3: Asia/Pacific 11 July, 2016 7:30 AM IST / 10:00 AM CST Please join Patrick Danaher, Senior Biostatistician with NanoString Technologies for "Gene Expression Signature Development: The Discovery Phase; State of the Field and Lessons Learned," as part of our Biomarkers Webinar Series. Webinar Live during: Jul 11, 2016 at 7:30am Direct Link for Sharing Multiplexed Gene Fusion Detection Simplified by Rich Boykin , Director of Bioinformatics NanoString’s Gene Fusion Panels provide a highly-multiplexed assay capable of simultaneously characterizing key fusion events and selected reference genes in a single tube. This webinar will discuss the design and development of assays for detection of Lung and Leukemia fusion genes. Times 10:00 AM (Beijing, Hong Kong) 7:30 AM (Sri Lanka) 2:00 PM UK Webinar Live during: Jun 27, 2016 at 6:00am On-Demand Direct Link for Sharing Profiling miRNA biomarkers using cells, FFPE, and clinical biofluids by Kirsteen Maclean , Sr. Field Application Scientist Recent studies have shown that changes in miRNA can be correlated with gene expression changes in development, differentiation, signla transduction, infection, aging, and disease. Biomarker discovery of miRNA Join the webinar and learn about NanoString’s nCounter® miRNA assay, applications such as biomarker discovery and signature development, data from various sample types, and capability of performing one assay for both miRNA and mRNA from the same sample. Times 6am PST (Seattle) 9am PST (Seattle) 2pm BST (England, Scotland) / 3pm CEST 5pm BST (England, Scotland) / 6pm CEST Webinar Live during: Jun 21, 2016 at 6:00am On-Demand Direct Link for Sharing Best Practices for Training and Validating Gene Expression Signatures from FFPE Samples by Wesley H. Buckingham , Manager, Dx Development Gene expression signatures are emerging as important prognostic and predictive tools for the treatment of cancer. The presentation will discuss best practices for development and validation of gene expression signatures based on NanoString’s experience in developing IVD test kits. Air Times June 13 6AM PST (Seattle) 2PM BST (England, Scotland) 3PM CEST (Germany) 9AM PST (Seattle) 5PM BST (England, Scotland) 6PM CEST (Germany) Webinar Live during: Jun 13, 2016 at 6:00am On-Demand Direct Link for Sharing Advancing Tumor Profiling with nCounter Vantage™ Assays by Gavin Meredith & Niro Ramachandran, With the growth of biomarker discovery, identification of novel cancer signatures has revealed the limitations of relying on a single analyte class to characterize tumors or predict their responses to therapies. NanoString has developed its novel 3D Biology™ technology and its Vantage™ line of products to meet the need for simultaneous analysis of DNA, RNA, and proteins. Webinar Live during: May 25, 2016 at 9:00am On-Demand Direct Link for Sharing Pages: 1 2 NEXT APPLICATIONS Applications Overview The Technology Gene Expression Analysis RNA:Protein Expression Single Cell GX Analysis miRNA Expression Analysis miRGE™ (miRNA & mRNA) Copy Number Variation lncRNA Analysis ChIP-String Analysis CANCER RESEARCH Cancer Research Overview nCounter® PanCancer Pathways nCounter® PanCancer Immune Profiling nCounter Vantage™ RNA FFPE Simplified Video: nCounter® & Cancer Video: nCounter® & FFPE PRODUCTS Products Overview nCounter Workflow nCounter® System nCounter SPRINT™ nCounter® MAX nCounter® Dx System w/ FLEX nCounter® Panel-Plus nCounter Vantage™ Gene Fusion nCounter® Gene Expression nCounter® Single Cell GX nCounter Vantage™ RNA nCounter Vantage™ RNA:Protein nCounter® Plex2™ for GX nCounter® miRNA nCounter miRGE™ nCounter® CNV nCounter® lncRNA nCounter® ChIP-String nSolver™ Analysis Software ORDERING INFORMATION ELEMENTS TagSets Elements TagSets Elements Workflow Fusion Genes nDESIGN GATEWAY nDesign Gateway Browse Probes Search Probes Manage CodeSets Video: nDesign Introduction nDesign Attributions COMMUNITY Community Overview Customer Profiles Core and Service Labs nCounter Publications NanoString Mailing List Upcoming Shows / Events NanoString Events Calendar SUPPORT Support Overview Request Information Global Distributors Product Literature MSDS Docs Software Support nCounter Videos Video: Cancer Research Video: FFPE Analysis Video: Single Cell Video: nDesign Introduction FAQs Contact Support Location and Contact Info Customer Login Customer Resources* Contact Us NanoString Technologies, Inc. 530 Fairview Avenue N Seattle, WA 98109 Tel: 1 888 358 6266 Fax: 1 206 378 6288 E-mail: info@nanostring.com SUBSCRIBE TO NEWSLETTER Follow Us Follow @nanostringtech © 2016 NanoString® Technologies, Inc. All rights reserved. Corporate Overview Investors Life Sciences Prosigna® Legal Privacy Policy Cookies Policy 1 888 358 6266